PT428 – Rick Doblin, Ph.D. – The Promise of MAPS' Phase III Data, Psychedelics and Adolescents, and the Need for Honest Drug Education

In this episode, recorded on the eve of MAPS' Psychedelic Science 2023, Kyle interviews MAPS' Founder and President, Rick Doblin, Ph.D. He begins with an overview of the fast-approaching (and largest ever) psychedelics conference, emphasizing its significant growth, many features, and bipartisan opening ceremony, then discusses MAPS' soon-to-be-released confirmatory Phase III data on MDMA-assisted therapy for PTSD, which should set the stage for legal MDMA and the increasing need for trained psychedelic therapists.  As the FDA is requiring studies on adolescents, he discusses this sensitive issue and questions why it's so controversial, since teenage years are often closer to both trauma and a more malleable brain, Indigenous traditions certainly didn't have age limits, and honest drug education – something that is absolutely necessary to fight the backlash against this quickly growing field – teaches us that it's not the substance; it's our relationship to it. Could not having these rites of passage be hurting us? He also discusses the natural vs. synthetic conflict; breathwork; whether or not cannabis is truly damaging to young minds; Federal rescheduling vs. state rescheduling; why it's controversial to give therapists MDMA in training; Gul Dolen's work with reopening critical periods; psychedelics in couples therapy; and much more. Click here to head to the show notes page.